On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...

Pfizer Inc PFE shares are dipping on Tuesday. The company announced a series of settlement agreements that extend the effective U.S. patent life of Vyndamax, its treatment for transthyretin‑mediated ...

Paying Patients to Access the Nation’s #1 Prescribed Oral Blood ThinnerPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Eliquis--The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) — (Pfizer NYSE: PFE) Alliance ...

The MarketWatch News Department was not involved in the creation of this content. -- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals ...

Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...